SDHB and hereditary leiomyomatosis and renal cell cancer: However, there are exceptions to this “3 cm guideline” for surgical intervention, for example, in patients with HLRCC, tumours are generally treated when diagnosed and not kept under surveillance and such an approach has also been suggested for renal tumours in patients with germline BAP1 and SDHB mutations.